Denali Advisors LLC Exelixis, Inc. Transaction History

Denali Advisors LLC

$916 Million
Q3 2024

A detailed history of Denali Advisors LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Denali Advisors LLC holds 8,431 shares of EXEL stock, worth $303,684. This represents 0.02% of its overall portfolio holdings.

Number of Shares

8,431

Holding current value

$303,684

% of portfolio

0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$21.96 - $27.6 $185,144 - $232,695	8,431 New	8,431 $218,000
Q3 2023 Oct 19, 2023	BUY	$19.04 - $22.74 $31,968 - $38,180	1,679 Added 7995.24%	1,700 $37,000
Q1 2023 Apr 21, 2023	SELL	$16.3 - $19.41 $11,067 - $13,179	-679 Reduced 97.0%	21 $0
Q3 2021 Oct 12, 2021	SELL	$16.3 - $21.14 $81,500 - $105,700	-5,000 Reduced 87.72%	700 $15,000
Q2 2021 Aug 20, 2021	SELL	$17.95 - $25.56 $14,360 - $20,448	-800 Reduced 12.31%	5,700 $104,000
Q1 2021 Apr 26, 2021	SELL	$20.53 - $25.22 $433,183 - $532,142	-21,100 Reduced 76.45%	6,500 $147,000
Q4 2020 Jan 20, 2021	SELL	$18.39 - $24.8 $101,145 - $136,400	-5,500 Reduced 16.62%	27,600 $554,000
Q3 2020 Oct 16, 2020	BUY	$20.67 - $26.94 $24,804 - $32,328	1,200 Added 3.76%	33,100 $809,000
Q2 2020 Jul 23, 2020	BUY	$16.46 - $27.42 $525,074 - $874,698	31,900 New	31,900 $757,000

Others Institutions Holding EXEL

# of Institutions

504

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

Black Rock Inc. New York, NY

33.5M
Shares

$1.21 Billion
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

29.3M
Shares

$1.06 Billion
0.01% of portfolio
Farallon Capital Management LLC San Francisco, CA

25.4M
Shares

$915 Million
3.31% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

15.4M
Shares

$553 Million
0.63% of portfolio
State Street Corp Boston, MA

11.4M
Shares

$412 Million
0.01% of portfolio

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Denali Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Denali Advisors LLC with notifications on news.

Account